WO2015011031A1 - Small molecule based conversion of somatic cells into neural crest cells - Google Patents
Small molecule based conversion of somatic cells into neural crest cells Download PDFInfo
- Publication number
- WO2015011031A1 WO2015011031A1 PCT/EP2014/065460 EP2014065460W WO2015011031A1 WO 2015011031 A1 WO2015011031 A1 WO 2015011031A1 EP 2014065460 W EP2014065460 W EP 2014065460W WO 2015011031 A1 WO2015011031 A1 WO 2015011031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- neural crest
- cell
- somatic
- schwann
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
Definitions
- This application relates to a method for differentiating somatic cells into multi-competent neural crest cells based on linked steps of chemically defined medium inductions.
- Neural crest cells are able to differentiate into numerous cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
- the ectopic genes often have to be stably integrated into the genome.
- the integrated genes may have undesired effects.
- the introduction of the proto-oncogene c-myc increased the risk of tumor formation in chimeric animals due to c-myc reactivation (Okita et al, 2007).
- the complex regulation machinery of the genome makes it rather difficult to predict long-term effects of genetic modifications.
- Li et al generated IPS cell by replacing certain genes with small molecules that modify specific signaling pathways like Wnt or TGF- ⁇ (Li et al, 2012). Yield and efficiency of gene-mediated conversion of fibroblasts into neurons was greatly increased by small molecule based inhibition of BMP, TGF ⁇ and GSK3b signaling (Ladewig et al, 2012). In line with these results, small molecules have also been proven valuable tools for directing the differentiation of stem cells. For example, inhibition of bone morphogenetic protein (BMP) and TGF- ⁇ signaling leads to highly efficient neural induction of stem cells (Chambers et al, 2009).
- BMP bone morphogenetic protein
- TGF- ⁇ signaling leads to highly efficient neural induction of stem cells (Chambers et al, 2009).
- somatic cells into multipotent neural crest cells, which is solely based on small molecule treatment and defined culture conditions and does not require to genetically modify the cells by the introduction of genes.
- This novel method employs a novel multikinase inhibitor to transdifferentiate somatic cells into a proliferative neural crest like stage.
- the neural crest cells can be differentiated into multiple cell types like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
- the differentiation of the neural crest cells into Schwann cells can be induced by a specific medium in combination with small molecule based inhibition of defined signaling pathways.
- the neural mature Schwann cells represent the glia cells of the peripheral nervous system (PNS).
- PNS peripheral nervous system
- Schwann cells fulfill numerous functions like immunoprotection, nutrient supply and myelination of the neurons.
- Schwann cell dysfunction is the cause for many neurological disorders of the peripheral nervous system, e.g. multiple sclerosis or myelination diseases.
- this novel cell conversion method does not require the expression of any ectopic gene, but is solely based on chemical treatment. It therefore represents a promising approach to generate patient specific neural crest cells or differentiated cells like Schwann cells, chondrocytes, smooth muscle cells or adipocytes.
- Neural Crest cells from somatic cells comprising:
- step (a) culturing somatic cells in medium supplemented with valproic acid, b) culturing the cells obtained in step (a) in a serum- free medium supplemented with N-
- the method does not comprise genetically modifying the somatic cells or the cells obtained in step (a) by the introduction of genes.
- step b) comprises culturing the cells in suspension culture.
- the serum-free medium of step b) is supplemented with an inhibitor of bone morphogenetic protein (BMP).
- BMP bone morphogenetic protein
- the inhibitor of BMP is noggin.
- the serum- free medium of step b) is supplemented with a small molecule inhibitor of Transforming growth factor beta (TGF ⁇ ).
- TGF ⁇ Transforming growth factor beta
- the small molecule inhibitor of TGF ⁇ is SB431542.
- the serum- free medium of step b) is supplemented with a small molecule inhibitor of glycogen synthase kinase 3 (GSK3P).
- GSK3P glycogen synthase kinase 3
- the inhibitor of GSK3P is 3-(3-Amino-phenyl)-4-(l-methyl-lH-indol- 3 -yl)-pyrro le-2 , 5 -dione .
- step a) comprises culturing the cells for 2 days.
- step b) comprises culturing the cells for 7 days.
- somatic cells are fibroblasts.
- somatic cells are human cells.
- the somatic cells are obtained from a subject suffering from a neurological disease.
- Neural Crest cells obtained by a method according to any of the above embodiments are provided.
- a differentiated cell selected from the group of Schwann Cell, chondrocyte, smooth muscle cell or adipocyte.
- Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by a method according to any of the above embodiments are provided.
- a biobank of Neural Crest cells or differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes are provided.
- the Neural Crest cells or differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes are used as in vitro model for neurological diseases.
- One embodiment comprises a therapeutic composition comprising Neural Crest cells or differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes or a biobank comprising these cells.
- One embodiment comprises use of N- ⁇ (3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy- benzoyl)-benzoylamino]-azepan-3-yl ⁇ -4-hydroxy-3,5-dimethyl-benzamide in a method for producing neural crest cells from somatic cells.
- One embodiment comprises use of 3-(3-Amino-phenyl)-4-(l-methyl-lH-indol-3-yl)- pyrrole-2,5-dione in a method for producing neural crest cells from somatic cells.
- Figure 1 Identification of a small molecule enhancing neural stem cell (NSC) proliferation and enabling conversion of fibroblasts into neurosphere-like structures.
- A Compound B promoted proliferation of ESC-NSCs in a dose-dependent manner. Proliferation was analysed by ATP assay and mean values of 2 experiments are shown.
- B Fibroblasts treated with Compound B formed sphere-like structure in suspension culture. Scale bars: 200 ⁇ .
- C Kinase selectivity profiling of Compound B. Orange bars represent kinases that were inhibited more than 80 percent.
- D Single or combined inhibition of Compound B targets by other compounds (compound targets displayed in parentheses in legend) had no or smaller effect on sphere formation of fibroblasts.
- Graphs show proliferation rate as fold change of initial cell number (left) and mean sphere diameter (right) at day 3 of suspension culture. Columns show mean +/- SD of three independent experiments. Data were evaluated using Student's t-test. *: p ⁇ 0.05 compared to DMSO control. +: p ⁇ 0.05 for Compound B compared to single inhibitors. E: Scheme of experimental setup for conversion of human fibroblasts into induced Schwann cells (iSCs).
- Figure 2 Conversion of human fibroblasts into a neural-crest like stage.
- A-D Secondary spheres at day 11 of conversion with bipolar cells growing out of spheres and expressing early neural plate markers Soxl and Nestin. Scale bars: 50 ⁇ .
- E Flow cytometry of converted neural crest cells (day 18) and fibroblasts (day 0) revealed downregulation of fibroblasts marker CD29 and upregulation of neural crest marker CD271. Lower panels show quantification of mean fluorescence intensity (MFI). Columns show mean +/-SD of three independent experiments and data were evaluated using Student's t-test.
- MFI mean fluorescence intensity
- F-I At day 18 of conversion, cells had migrated out of spheres and expressed neural crest markers Snail, SoxlO, FoxD3, and AN2. Scale bars: ⁇ .
- J-M Non-neural differentiation of neural crest-like cells. Cultivation in specific differentiation media resulted in formation of adipocytes (J), smooth muscle cells (K), and chondrocytes (L, M). Scale bars: 50 ⁇ (J), ⁇ (K).
- FIG. 3 Differentiation of transient precursors into induced Schwann cells (iSCs).
- A-D iSCs express Schwann cell marker proteins. Scale bars: 50 ⁇ .
- F Principal component analysis of whole transcriptome expression profiles from cells at day 0 (fibroblasts), d7 (early tP), dl l (early tP), dl8 (late tP), day 39 (iSCs), and primary Schwann cells (pSCs).
- FIG. 4 Functionality of iSCs in co-culture with neuronal cells.
- G Co-culture of iSCs with primary rat DRG neurons.
- iSCs form single myelinated fragments (arrowhead) detected by co-localization of MBP staining (yellow) and neurofilament (NF) staining (magenta). Scale bars: 20 ⁇ .
- Figure 5 Characterization of human fibroblasts used for iSC generation.
- A-C Human fibroblasts do not express neural crest or Schwann cell markers.
- A Phase contrast image of fibroblasts. Scale bar: 50 ⁇ .
- B Flow cytometry analysis of fibroblasts showing that initial fibroblast population does not contain cells expressing the neural crest marker CD271.
- C Immuno staining for neural crest and Schwann cell markers. Nuclei were visualized with Hoechst staining.
- FIG. 7 (A, B) Conversion protocol did not yield neurons as shown by negative Map2 staining at day 31. Nuclei were visualized with Hoechst staining. Scale bars: ⁇ .
- C, D Whole gene expression profiles during conversion process.
- C Heat map of the differentially expressed genes (>10 fold change during at least 1 time point) at day 11 (early tP), dl8 (late tP), and day 39 (iSCs) relative to day 0 (fibroblasts). Clusters for globally down-regulated genes (blue) and up- regulated genes (red) were generated using average linkage and Euclidean distance. Biological process GO terms were used for cluster annotation. For each stage, data from at least two independent assays were analysed.
- D Heat map showing differential expression of the neurotrophic factors. Log2 expression ratios indicate down-regulation in blue and up-regulation in red. Data from at least two independent experiments are shown.
- Figure 8 Time course of co-culture of NSC-derived neurons on POL, cell tracker labeled fibroblasts or cell tracker labeled iSCs. Overlays of phase contrast images and cell tracker signal (red). NSC-neurons can be identified by characteristic small, dark soma. At day 1, NSC-neurons have attached on all three surfaces (A-C). Prolonged co-culture with fibroblasts led to aggregation of neurons and poor neurite outgrowth (E, H). Co-culture with iSCs resulted in proliferation and formation of multicellular network (F, I). Scale bars: ⁇ . J: Co-culture with iSCs led to an increased number of NSC-neurons compared to NSC-neurons grown on POL. Neurons were identified as cell tracker negative cells at day 13 of co-culture. Columns show mean +/- SD of three independent experiments. Data were evaluated using Student's t-test.
- NCCs neural crest cells
- SC progenitors a dividing population of SC progenitors.
- the NCCs can be expanded and then - in a second step - differentiated into mature SCs.
- the NCCs can also give rise to chondrocytes, smooth muscle cells or adipocytes.
- Neural crest cells are multipotent cells that originate at the border of the neural plate and non-neural ectoderm during embryogenesis and give rise to various cell types e.g. Schwann cells, peripheral neurons, melanocytes, smooth muscle cells, and cartilage.
- Neural crest specification is a highly complex process that is regulated by numerous signaling cues like for example bone morphogenic protein (BMP), Sonic Hedgehog (Shh), Wnt, Fibroblast growth factor (Fgf), and Notch (Stuhlmiller and Garcia-Castro, 2012).
- BMP bone morphogenic protein
- Sonic Hedgehog Shh
- Wnt Wnt
- Fibroblast growth factor Fgf
- Notch Notch
- specification of neural crest is closely linked to neuroepithelial fate determination. Differentiation of pluripotent stem cells into neural cells in vitro often yields a small proportion of NCCs (Chambers et al, 2009).
- the inventors of the present invention found that the combination of neural inductive cues together with NCC specifiers induces a NCC fate in fibroblasts.
- Compound B N- ⁇ (3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]- azepan-3-yl ⁇ -4-hydroxy-3,5-dimethyl-benzamide, also referred to as 3,5-Dimethyl-4- hydro xybenzoic acid ⁇ (3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]- azepan-3-yl ⁇ - amide hydrochloride, see e.g. WO03/076429) can induce the reprogramming of somatic cells into neural crest cells.
- the inventors of the present invention show that this compound selectively promotes proliferation of neural stem cells with no effect
- Neural Crest cells from somatic cells comprising:
- step (a) culturing somatic cells in medium supplemented with valproic acid, b) culturing the cells obtained in step (a) in a serum- free medium supplemented with N- ⁇ (3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]-azepan-3-yl ⁇ -4- hydro xy-3,5-dimethyl-benzamide.
- the method does not comprise genetically modifying the somatic cells or the cells obtained in step (a) by the introduction of genes.
- Media suitable for culturing the somatic cells in step a) are any known media suitable for growing a certain somatic cell type in a dish.
- fibroblasts are grown in low serum fibroblast medium (e.g. FibroGro, Millipore).
- Media suitable for culturing the cells in step b) are any serum-free media, preferably supplemented with one or more growth factors selected from the group of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), brain derived neutrotrophic factor (BDNF), Heparin, Delta like protein 4 (D114), Jaggedl, Sonic Hedgehog (SHH), fibroblast growth factor 8 (FGF8).
- bFGF basic fibroblast growth factor
- EGF epidermal growth factor
- BDNF brain derived neutrotrophic factor
- D114 Delta like protein 4
- SHH Sonic Hedgehog
- FGF8 fibroblast growth factor 8
- the term "somatic cell” as used herein refers to any cell forming the body of an organism that are not germ line cells (e. g. sperm and ova, and the cells from which they are made (gametocytes)) and undifferentiated stem cells. Internal organs, skin, bones, blood and connective tissue are all made up of somatic cells
- the somatic cells are fibroblasts.
- Fibroblasts useful therein are for example lung fibroblasts and foreskin fibroblasts.
- the somatic cells used for conversion into neural crest cells are of mammalian origin, most preferably of human origin.
- Said human somatic cells can be obtained from a healthy individual or from a patient.
- Preferably said somatic cells are chosen from the group of fibroblast cells, adipocytes or keratinocytes.
- These donor cells can be easily obtained from any suitable source.
- Preferred herein are sources that allow isolation of donor cells without invasive procedures on the human body. Methods for isolating fibroblast cells are well known in the art.
- Fibroblast cells may be obtained from any suitable source, for example from various organ tissues or skin tissue.
- Preferred fibroblasts are lung fibroblasts, foreskin fibroblasts, and adult dermal fibroblasts.
- said human fibroblasts are obtained from a patient, for example by skin biopsy (e.g. Reprogramming of human somatic cells to pluripotency with defined factors. George Q. Daley et al. Nature 2008; A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin, Normand et al. In Vitro Cellular & Developmental Biology - Animal, 1995).
- Adipocytes and keratinocytes can also be easily derived by skin biopsy or plucked hair (Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells, Belmonte et al. Nature Protocols 2010) and are also preferred donor cells for the method of this invention.
- Other somatic cells suitable for conversion into neural crest cells are leucocytes cells obtained from blood samples or epithelial cells or other cells obtained from urine samples.
- neural crest cells refers to a subset of multipotent cells which express at least one of the neural markers selected from the group of SoxlO, Snail, Twistl, Krox20, CD271, FoxD3, AN2.
- the neural crest cells obtained by the method disclosed herein express all of the neural markers SoxlO, Snail, Twistl, Krox20, CD271, FoxD3, AN2.
- the neural crest cells obtained by the method described herein are also referred to as "iNCCs”: induced neural crest cells.
- Neural crest cells can be expanded indefinitely and may differentiate into Schwann cells, chondrocytes, smooth muscle cells, and adipocytes.
- reprogramming refers to one or more steps needed to convert a somatic cell to a less-differentiated cell, for example for converting fibroblast cells, adipocytes or keratinocytes into neural crest cells. Reprogramming of a somatic cell to a neural crest cell is achieved by the method disclosed therein.
- step b) comprises culturing the cells in suspension culture.
- the suspension culture promotes formation of sphere-like structures and therefore selects for the cells that undergo reprogramming.
- the term "suspension culture” as used herein refers to the culture of cells such that the cells do not adhere to the solid support or the culture vessel. To transfer ceils into a suspension culture, they are for example removed from the culture receptacle by a cell scraper and transferred to sterile low attachment plates containing culture medium, which do not allow adhesion of the cells to the surface of the plate. Thus, the cells are cultured in suspension without adherence to a matrix or the bottom of the dish.
- the serum-free medium of step b) is supplemented with an inhibitor of bone morphogenetic protein (BMP).
- BMP bone morphogenetic protein
- the inhibitor of BMP is noggin (Synonyms: NOG; SYM1 ; SYNS1).
- TGFP Transforming growth factor beta
- the inhibitor of TGF ⁇ is SB431542 (see. E.g. Laping, NJ; Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (2002).
- TGF transforming growth factor
- the serum- free medium of step b) is supplemented with a small molecule inhibitor of glycogen synthase kinase 3 (GSK3P).
- GSK3P glycogen synthase kinase 3
- the inhibitor of GSK3P is 3-(3-Amino-phenyl)-4-(l-methyl-lH-indol-3-yl)-pyrrole-2,5-dione, also referred to as "compound 21" or "CP21" herein; see e.g. L. Gong et al; Bioorganic& Medicinal Chemistry Letters 20 (2010), 1693-1696.
- the serum- free medium of step b) is supplemented with inhibitors of BMP, TGF ⁇ , and GSK3p. In one embodiment, the serum- free medium of step b) is
- the serum-free medium of step b) is supplemented with 0.1- 1 ⁇ g/ ml noggin, 0.1-5 ⁇ CP21 and 1-50 ⁇ SB431542. In one embodiment, the serum-free medium of step b) is supplemented with 0.5 ⁇ g/ ml noggin, 1 ⁇ CP21 and 10 ⁇ SB431542.
- One embodiment comprises use of N- ⁇ (3R,4R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy- benzoyl)-benzoylamino]-azepan-3-yl ⁇ -4-hydroxy-3,5-dimethyl-benzamide in a method for producing neural crest cells from somatic cells.
- One embodiment comprises use of 3-(3-Amino-phenyl)-4-(l-methyl-lH-indol-3-yl)- pyrrole-2,5-dione in a method for producing neural crest cells from somatic cells.
- step a) comprises culturing the cells for 2 days.
- step b) comprises culturing the cells for 7 to 14 days. In one embodiment step b) comprises culturing the cells for 7 days. In one embodiment step b) comprises culturing the cells for 14 days.
- somatic cells are human cells.
- One preferred aspect of the present invention is a method for generating patient specific neural crest cells.
- the somatic cells are obtained from a subject suffering from a neurological disease.
- Neurode logical disease as used herein is defined as a disorder of the nervous system, and include disorders that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system).
- neurological disease includes any disease wherein the function of neural crest cells or Schwann cells is impaired, altered or disrupted.
- Examples of neurological diseases connected with Schwann cells are Demyelinating diseases, Multiple sclerosis, Myelopathies, Experimental allergic
- EAE encephalomyelitis
- ADAM acute disseminated encephalomyelitis
- postinfectious or postvaccinal encephalomyelitis peripheral neuropathies, Schwannomatosis, Charcot-Marie- Tooth disease, Guillain-Barre Syndrome, Chronic inflammatory demyelinating
- CIDP polyradiculoneuropathy
- Another aspect of the present invention is a method for generating neural crest cells from somatic cells obtained from a healthy individual.
- patient specific neural crest cell refers to neural crest cells obtained from somatic cells of a patient and are also referred to as autologous neural crest cells.
- neural crest cells obtained from a healthy individual refers to neural crest cells obtained from somatic cells of an individual that is not suspected to suffer from any disorder or disease.
- a population of neural crest cells produced by any of the foregoing methods is provided.
- the population of neural crest cells is patient specific, i.e. derived from somatic cells obtained from diseased individuals.
- said population of cells is obtained from a healthy individual.
- the neural crest cells can be expanded indefinitely. Culturing is easy and well characterized. It is possible to freeze and thaw neural neural crest cells aliquots reproducibly.
- Patient derived neural crest cells represent a disease relevant in vitro model to study the pathophysiology of neurological diseases. Conversion of patients specific somatic cells directly to neural crest cells represents an easy accessible and reproducible technology to generate BioBanks of patient specific neural crest cells.
- BioBank comprising patient specific neural crest cells.
- BioBank comprising different populations of neural crest cells obtained from healthy individuals is generated.
- BioBank as used herein means a library of biological samples taken from different individuals or species.
- the archived collection of specimen and associated data is intended for research purposes with the aim of addressing neurological diseases like Demyelinating diseases, Multiple sclerosis, Myelopathies, Experimental allergic encephalomyelitis (EAE), acute disseminated encephalomyelitis (ADEM), postinfectious or postvaccinal encephalomyelitis, peripheral neuropathies, Schwannomatosis, Charcot-Marie-Tooth disease, Guillain-Barre Syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- neurological diseases like Demyelinating diseases, Multiple sclerosis, Myelopathies, Experimental allergic encephalomyelitis (EAE), acute disseminated encephalomyelitis (ADEM), postinfectious or postvaccinal encephalomyelitis, peripheral neuropathies, Schwannomatosis, Charcot-Marie-Tooth disease, Guillain-Barre Syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- steps b) incubating the product of steps b) under conditions suitable for differentiation of the neural crest cells into a differentiated cell selected from the group of Schwann Cell, chondrocyte, smooth muscle cell or adipocyte.
- the term “differentiating”, “differentiation” refers to one or more steps to convert a less-differentiated cell into a somatic cell, for example to convert a neural crest cell into Schwann cells, chondrocytes, smooth muscle cells, and adipocytes.
- Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by a method according to any of the above embodiments are provided.
- the Schwann Cells, chondrocytes, smooth muscle cells or adipocytes are patient specific, i.e. derived from somatic cells obtained from diseased individuals.
- said population of cells is obtained from a healthy individual.
- patient derived Schwann cells represent a disease relevant in vitro model to study the pathophysiology of neurological diseases.
- Conversion of patients specific somatic cells to Schwann Cells, chondrocytes, smooth muscle cells or adipocytes represents an easy accessible and reproducible technology to generate BioBanks of patient specific Schwann Cells, chondrocytes, smooth muscle cells or adipocytes.
- a BioBank comprising patient specific Schwann Cells, chondrocytes, smooth muscle cells or adipocytes is envisaged.
- a BioBank comprising different populations of Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained from healthy individuals is generated.
- BioBank as used herein means a library of biological samples taken from different individuals or species.
- the archived collection of specimen and associated data is intended for research purposes with the aim of addressing diseases, for example neurological diseases like Demyelinating diseases, Multiple sclerosis, Myelopathies, Experimental allergic encephalomyelitis (EAE), acute disseminated encephalomyelitis (ADEM), postinfectious or postvaccinal encephalomyelitis, peripheral neuropathies, Schwannomatosis, Charcot-Marie- Tooth disease, Guillain-Barre Syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- EAE Experimental allergic encephalomyelitis
- ADAM acute disseminated encephalomyelitis
- CIDP Chronic inflammatory demyelinating polyradiculoneuropathy
- the neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by this method are used as an in vitro model to study the pathophysiology of neurological diseases.
- the neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by the method of the invention can be used for screening for compounds that reverse, inhibit or prevent neurological diseases.
- they can be used for screening for compounds that reverse, inhibit or prevent neural side effects of medicaments, for example diabetes medicaments.
- said neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by the method of the invention described herein are derived from diseased subjects.
- the neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by this method are used for screening and evaluating new targets and compounds for treatment of neurological diseases.
- the neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by this method are derived from individuals affected by neurological diseases. Differentiating neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes from diseased subjects represents a unique opportunity to early evaluate drug safety in a human background paradigm.
- the differentiated Schwann Cells obtained by this method are used as an in vitro model of the peripheral nervous system.
- the invention provides a therapeutic composition comprising cells produced by any of the foregoing methods or containing any of the foregoing cell populations.
- the therapeutic compositions further comprise a physiologically compatible solution including, for example, artificial cerebrospinal fluid or phosphate-buffered saline.
- Said therapeutic composition can be used to treat, prevent, or stabilize a neurological disease such as for example, Demyelinating diseases, Multiple sclerosis, Myelopathies, Experimental allergic encephalomyelitis (EAE), acute disseminated encephalomyelitis (ADEM) , postinfectious or postvaccinal encephalomyelitis, peripheral neuropathies, Schwannomatosis, Charcot-Marie- Tooth disease, Guillain-Barre Syndrome, Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- a neurological disease such as for example, Demyelinating diseases, Multiple sclerosis, Myelopathies, Experimental allergic encephalomyelitis (EAE), acute disseminated encephalomyelitis (ADEM) , postinfectious or postvaccinal encephalomyelitis, peripheral neuropathies, Schwannomatosis, Charcot-Marie- Tooth disease, Guillain-Barre Syndrome, Chronic inflammatory demyelinating
- fibroblast cells, keratinocytes or adipocytes may be obtained by skin biopsy from the individual in need of treatment or from a healthy individual and reprogrammed to neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes by the method of the invention.
- the neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained by this method are harvested and introduced into the individual to treat the condition.
- the neural crest cells obtained by this method are cultured under conditions suitable for differentiation into differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes prior to introduction into the individual, and may be used to replace or assist the normal function of diseased or damaged tissue.
- the great advantage of the present invention is that it provides an essentially limitless supply of patient specific human neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes or compatible neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes from healthy individuals with the same HLA type suitable for transplantation.
- autologous and/or compatible cells offers a major advantage over the use of non-autologous cells, which are likely to be subject to immunological rejection. In contrast, autologous cells are unlikely to elicit significant immunological responses.
- Another embodiment of the invention is the use of biobanks of human neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes for therapy of neurological diseases.
- the biobanks preferably comprise human neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes obtained from patients or healthy individuals with several HLA types.
- Transplanting cells obtained from a healthy donor to an individual in need of treatment with a compatible HLA type obviates the significant problem of rejection reactions normally associated with heterologous cell transplants.
- rejection is prevented or reduced by the administration of immunosuppressants or anti-rejection drugs such as cyclosporin.
- immunosuppressants or anti-rejection drugs such as cyclosporin.
- drugs have significant adverse side-effects, e.g., immunosuppression, carcinogenic properties, kidney toxicity as well as being very expensive.
- the present invention should eliminate, or at least greatly reduce, the need for anti-rejection drugs, such as cyclosporine, imulan, FK-506, glucocorticoids, and rapamycin, and derivatives thereof.
- neural crest cells, differentiated Schwann Cells, chondrocytes, smooth muscle cells or adipocytes may be administered to the mammal in a single dose or multiple doses.
- the doses may be separated from one another by, for example, one week, one month, one year, or ten years.
- One or more growth factors, hormones, interleukins, cytokines, small molecules or other cells may also be administered before, during, or after administration of the cells to further bias them towards a particular cell type.
- stem cell refers to a cell that has the ability for self-renewal.
- An "undifferentiated stem cell” as used herein refers to a stem cell that has the ability to differentiate into a diverse range of cell types.
- pluripotent stem cells refers to a stem cell that can give rise to cells of multiple cell types.
- Pluripotent stem cells include human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs).
- Human induced pluripotent stem cells can be derived from reprogrammed somatic cells, e.g. by transduction of four defined factors (Sox2, Oct4, Klf , c-Myc) by methods known in the art.
- SCC058 foreskin fibroblasts were cultured at 37°C and 5% C0 2 in low serum FibroGro (Millipore). For conversion, 7300 cells/cm 2 were seeded in fibroblast medium containing lmM Valproic acid (VP A, Sigma). Then, cells were treated for two days with ImM VP A, and 6 ⁇ g/ml polybrene (Millipore) and subsequently transferred to low attachment plates in NSC medium for sphere formation.
- VP A lmM Valproic acid
- NSC medium consisted of NeuroCult NS-A proliferation medium (StemCell Technologies) supplemented with Penicillin/streptomycin, bFGF (20ng/ml), EGF (20ng/ml), BDNF (20ng/ml), Heparin (2 ⁇ g/ml), D114 (500ng/ml), Jaggedl (500ng/ml), SHH (500ng/ml, peprotech), Ascorbic Acid (0.2mM, Sigma), FGF8a (lOOng/ml), 10% NSC-CM (medium conditioned by ESC-NSCs), and Compound B (2 ⁇ , Roche).
- Compound B has been described e.g. in WO03/076429 and has the following structure:
- CP21 is a novel, highly selective GSK3P inhibitor: Systematic name 3-(3-Amino-phenyl)-
- differentiation medium comprising N2B27 (1 : 1 DMEM/F12 and Neurobasal with beta-mercaptoethanol (50 ⁇ ), B27 supplement without vitamin A (1 :50, Invitrogen), and N2 supplement (1 : 100, Invitrogen)) supplemented with antibiotics, BDNF (20ng/ml), GDNF (20ng/ml), Laminin ( ⁇ g/ml), Ascorbic Acid (0.2 mM) and dibutyryl-cAMP (0.5 mM, Sigma). Every other day, 50% of medium was exchanged. For the first seven days of differentiation, medium was supplemented with the inhibitor mix.
- adipogenic differentiation medium containing DMEM, 7.5% knockout serum replacement (KOSR, Invitrogen), 0.5%> non-essential amino acids, 1%) penicillin and streptomycin, 0.1 ⁇ dexamethasone, 10 ⁇ g/ml insulin (Sigma) and 0.5 ⁇ rosiglitazone. Medium was changed every other day. After 4 weeks, cells were fixed with 4% PFA and stained with Oilred or antiSMA, respectively.
- chondrogenesis secondary spheres were collected by centrifugation and cultured as pellet in DMEM high glucose supplemented with glutamine, pyruvate, antibiotics, NEAA, 10%> FCS, and lOng/ml TGF ⁇ . After four weeks, pellet was fixed with 4%PFA and analysed by Alcian blue staining.
- Embryonic stem cell-derived neural stem cells were generated as previously described using dual SMAD inhibition protocol (Chambers et al, 2009). NSCs were cultured on POL coated plates at 37°C, 5%C0 2 in N2B27 supplemented with bFGF (lOng/ml), EGF (lOng/ml), BDNF (20ng/ml). For Compound B identification, NSCs were seeded on POL coated plates at 21000 cells/cm 2 in N2B27. After cell attachment (4h), compounds were added at indicated concentrations. Negative control cells were treated with DMSO. Cells were incubated for four days and subsequently the amount of ATP was determined using the CellTiterGlo® kit (Promega) according to the manufacturer's instructions.
- NSCs were cultured in differentiation medium for 13 days. NSC-neurons were detached with Accutase and then seeded in differentiation medium on POL only, fibroblasts or iSCs at 120000 NSC-neurons/12well. Fibroblasts and iSCs had been previously labeled with CFSE cell tracker (Invitrogen, 10 ⁇ for 20min). Every other day, 50% of medium was exchanged. Cells were fixed with 4%PFA at day 13 of co-culture.
- Oilred staining cells were fixed with 4% PFA for 15min. After washing with PBS, cells were incubated in Oilred staining solution (0.21% Oilred in 60% isopropanol) at room temperature for one hour. Subsequently, cells were washed 3-5 times with PBS and analysed.
- Oilred staining solution 0.21% Oilred in 60% isopropanol
- cells were washed 3-5 times with PBS and analysed.
- Alcian blue staining of chondrogenesis cell pellet was fixed with 4% PFA for 30min. The pellet was then washed three times with PBS and incubated in Alcian blue staining solution at room temperature overnight. Pellet was destained (20min room temperature, three times), transferred to PBS and analysed.
- RNA quality assessment and quantification was performed using micro fluidic chip analysis on an Agilent 2100 bioanalyzer (Agilent Technologies). On a Biomek FXp workstation (Beckman Coulter), lOng of total RNA was reverse transcribed using the NuGen Ovation Pico WTA Systems V2, followed by fragmentation, and 3 '-biotin- labeling with the NuGen Encore Biotin module (NuGEN Technologies).
- Compound B was shown to selectively promote proliferation of neural stem cells with no effect on mesenchymal stem cells (Figure 1 A).
- Figure 1 A To analyze the capacity of Compound B to induce a NC progenitor stage in fibroblasts, a sphere formation assay was performed. This assay has been used in numerous studies to identify and select cells with stem cell features from various tissues (Dontu et al, 2003; Seaberg et al, 2004; Toma et al, 2001; Tropepe, 2000). Compound B treatment resulted in a significant increase in both sphere size and total cell number (Figure IB).
- NCCs are characterized by their capacity to give rise to various different cell types, we tested the ability of the converted cells to give rise to non-neural cell types that originate from NC.
- differentiation media converted cells gave rise to adipocytes (identified by OilRed stain), cartilage (identified by Alcian Blue), and SMA positive smooth muscle cells confirming their multipotent differentiation capacity.
- adipocytes identified by OilRed stain
- cartilage identified by Alcian Blue
- SMA positive smooth muscle cells confirming their multipotent differentiation capacity.
- Schwann cells fulfill numerous functions to support the growth, differentiation and survival of neuron progenitors and neurons. Additionally, their protrusions form the myelin sheaths insulating one axon from another.
- iSCs able to support neuron differentiation and survival
- a co-culture experiment was performed. Human neural stem cells derived from embryonic stem cells were induced to differentiate into neurons (NSC-neurons). After 13 days, NSC-neurons were detached and plated on either poly-ornithine, cell tracker labeled fibroblasts or iSCs. NSC-neurons attached well in all three conditions. NSC-neurons plated on POL continued to differentiate and form a network of neurites.
- Image quantification revealed that Map2 positive area as well as number and total length of neurites were significantly increased in the iSC/NSC-neuron co-culture compared to NSC-neurons grown alone (Figure 4). Moreover, total number of neurons was also increased when cells were co-cultures with iSCs ( Figure 8J). This suggests that iSCs positively affected neuron survival and differentiation. Moreover, co-culture with fibroblasts led to significant decrease in neurite number and length confirming that the beneficial effect of the iSCs is really due to their cellular phenotype and not to their cell type of origin.
- iSCs significantly support neuron differentiation and survival and are able to form myelin sheaths, albeit at low frequency.
- the conversion process into iSCs also includes the adoption of functional features of physiological Schwann cells.
- Compound B induced the first step of conversion towards a NCC phenotype evaluated by the capacity of sphere formation, proliferation in suspension, and attachment of spheres to laminin.
- Kinase profiling identified AMPK, MSK1, PKA, ROCK2, PKGa, and SGK1 as main targets of Compound B.
- SGK1 is involved in cellular stress response and its upregulation correlates with occurrence of cell death in neurodegenerative disease (Schoenebeck et al, 2005). In our approach SGK1 inhibition might therefore enhance survival of cells that converted towards a neural fate.
- AMPK functions as key energy sensor of cells.
- AMPK activation inhibits IPS generation by preventing transition to a glycolytic metabolism necessary for reprogramming (Vazquez-Martin et al, 2012). Such a metabolic barrier might also be crucial in the current conversion protocol where cells are transferred form serum-containing fibroblast medium to serum-free neural medium.
- Compound B-mediated AMPK inhibition possibly prevents cellular responses to metabolic stress thus allowing continued glycolysis providing the energy required for the conversion process.
- Another Compound B target is the Rho-associated kinase ROCK2.
- Rock inhibition evokes a proliferative, stem cell- like phenotype in normal and tumor cells from various tissues (Liu et al, 2012b; Terunuma et al, 2010). Furthermore, inhibition of Rock signaling promotes emigration of neural crest cells (Groysman et al, 2008) and has neuroprotective effects (Ding et al, 2009). Thus, additionally to its effect on sphere formation, Rock inhibition probably enhances adoption of features of migrating neural crest cells and promotes survival of these cells.
- Compound B influences the conversion of fibroblasts in two ways. First, it enables transition to a reprogrammable state by preventing stress-induced cell death, allowing sphere formation and providing the required metabolic state. Second, it enhances the adoption of neural crest features which is potentially also mediated by the presence of known NC specifying growth factors like Shh, FGF, and Notch-ligands Jagged and D114.
- TGF ⁇ , BMP, and GSK3P signaling Modification of these pathways is known to direct differentiation of embryonic stem cells to neuroepitelial and/ or neural crest fates (Chambers et al, 2009; Menendez et al, 2011).
- Tgf- ⁇ , BMP, and GSK3P should therefore enhance the conversion towards neural crest.
- BMP and TGF- ⁇ signaling promote non-neural differentiation of neural crest cells into mesenchymal cell types (Chung et al, 2009; John et al, 2011; Shah et al, 1996).
- inhibition of these pathways in our protocol also serves the purpose to suppress the formation of these non-neural cells to favor Schwann cell formation.
- Schwann cells play an important role in development, homeostasis and diseases of the peripheral nervous system (Bhatheja and Field, 2006).
- human Schwann cells can be derived from pluripotent stem cells (Liu et al, 2012a) or as primary cells from peripheral nerve tissue (Casella et al, 1996). While the latter approach only yields a restricted amount of cells, the use of pluripotent stem cells is linked to ethical constraints, potential tumorigenicity and - in case of IPS cells - the introduction of ectopic genes.
- the chemical conversion of fibroblasts to iSCs represents a novel source for Schwann cells without the involvement of pluripotent stages or genetic modifications.
- iSCs arise from differentiation of rare stem cell populations in the fibroblast culture instead of originating from a real conversion process. Indeed, it has been shown that so called skin derived precursors can be obtained from rodent and human (Toma et al, 2001; Toma et al, 2005). These precursors show NC stem cell properties and can also differentiate into Schwann cells (Fernandes et al, 2004; McKenzie et al, 2006). However, in the beginning of the conversion process cell numbers increased more than 2.5 fold within four days. To reach this proliferation rate, the proportion of stem cells in the initial culture would have to be around 30 percent which is far above reported frequencies for this population in skin (about one percent) (Hunt et al, 2008).
- iSCs indeed originated from fibroblasts that converted towards another cellular phenotype.
- Schwann cell identity of the converted cells was confirmed by glia morphology, expression of numerous Schwann cells markers, electrophysiology, and the ability to efficiently support of neuron differentiation and survival in vitro.
- iSCs appeared to be able of myelinate neurons in vitro, albeit at low frequency. However, this could be due to the subtype of NSC-derived neurons and additional cues that are present during myelination in vivo might be required to achieve the same result in vitro.
- Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav lmmun 23, 1083-1088.
- ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.
- AMP-activated protein kinase provides a metabolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 11, 974-989.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Rheumatology (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480041377.XA CN105392881B (en) | 2013-07-23 | 2014-07-18 | Somatic cell based on small molecule conversion into neural crest cell |
BR112015032235A BR112015032235A2 (en) | 2013-07-23 | 2014-07-18 | method of producing neural crest cells, neural crest cells, schwann cells, chondrocytes, smooth muscle cells or adipocytes, neural crest cell biobank, cell use, therapeutic composition and methods and uses |
KR1020167001943A KR20160033703A (en) | 2013-07-23 | 2014-07-18 | Small molecule based conversion of somatic cells into neural crest cells |
JP2016528451A JP6474806B2 (en) | 2013-07-23 | 2014-07-18 | Conversion of somatic cells into neural crest cells by small molecules |
CA2914520A CA2914520A1 (en) | 2013-07-23 | 2014-07-18 | Small molecule based conversion of somatic cells into neural crest cells |
MX2016000557A MX2016000557A (en) | 2013-07-23 | 2014-07-18 | Small molecule based conversion of somatic cells into neural crest cells. |
EP14744018.4A EP3024928B1 (en) | 2013-07-23 | 2014-07-18 | Small molecule based conversion of somatic cells into neural crest cells |
RU2016105998A RU2016105998A (en) | 2013-07-23 | 2014-07-18 | CONVERSION BASED ON SMALL SOMATIC CELL MOLECULES IN NEURAL COMB CELLS |
US15/004,745 US10724000B2 (en) | 2013-07-23 | 2016-01-22 | Small molecule based conversion of somatic cells into neural crest cells |
HK16110594.1A HK1222414A1 (en) | 2013-07-23 | 2016-09-06 | Small molecule based conversion of somatic cells into neural crest cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13177606.4 | 2013-07-23 | ||
EP13177606 | 2013-07-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/004,745 Continuation US10724000B2 (en) | 2013-07-23 | 2016-01-22 | Small molecule based conversion of somatic cells into neural crest cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015011031A1 true WO2015011031A1 (en) | 2015-01-29 |
Family
ID=48875546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/065460 WO2015011031A1 (en) | 2013-07-23 | 2014-07-18 | Small molecule based conversion of somatic cells into neural crest cells |
Country Status (11)
Country | Link |
---|---|
US (1) | US10724000B2 (en) |
EP (1) | EP3024928B1 (en) |
JP (1) | JP6474806B2 (en) |
KR (1) | KR20160033703A (en) |
CN (1) | CN105392881B (en) |
BR (1) | BR112015032235A2 (en) |
CA (1) | CA2914520A1 (en) |
HK (1) | HK1222414A1 (en) |
MX (1) | MX2016000557A (en) |
RU (1) | RU2016105998A (en) |
WO (1) | WO2015011031A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017069222A1 (en) * | 2015-10-21 | 2017-04-27 | 京都府公立大学法人 | Cell preparation method |
WO2018090006A1 (en) * | 2016-11-14 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Methods for drug discovery using stem cell-derived schwann cells |
CN109312306A (en) * | 2016-04-22 | 2019-02-05 | 大日本住友制药株式会社 | The method for generating retinal tissue |
US11214771B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
US11959100B2 (en) | 2017-11-30 | 2024-04-16 | Kyoto University | Method for culture of cells |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2018225868A1 (en) * | 2017-06-10 | 2020-04-09 | 株式会社島津製作所 | Method for predicting differentiation ability to chondrocytes based on gene expression profile of iPS cells |
KR102010478B1 (en) * | 2017-11-01 | 2019-08-13 | 차의과학대학교 산학협력단 | Composition and kit for differentiating stem cells to neural crest stem cell, and method using the same |
EP3807402A4 (en) * | 2018-06-14 | 2022-04-27 | Academia Sinica | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells |
CN112538458A (en) * | 2020-11-26 | 2021-03-23 | 北京赛尔湃腾科技咨询合伙企业(有限合伙) | Method for reprogramming cells |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076429A2 (en) * | 2002-03-12 | 2003-09-18 | F. Hoffmann-La Roche Ag | Azepane derivatives and their use as atk1 inhibitors |
WO2010108126A2 (en) * | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
WO2012006577A2 (en) * | 2010-07-08 | 2012-01-12 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
WO2012022725A2 (en) * | 2010-08-19 | 2012-02-23 | F. Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120021519A1 (en) * | 2008-09-19 | 2012-01-26 | Presidents And Fellows Of Harvard College | Efficient induction of pluripotent stem cells using small molecule compounds |
CA2822638C (en) * | 2010-12-22 | 2021-02-16 | Fate Therapeutics, Inc. | Cell culture platform for single cell sorting and enhanced reprogramming of ipscs |
-
2014
- 2014-07-18 WO PCT/EP2014/065460 patent/WO2015011031A1/en active Application Filing
- 2014-07-18 RU RU2016105998A patent/RU2016105998A/en not_active Application Discontinuation
- 2014-07-18 CA CA2914520A patent/CA2914520A1/en not_active Abandoned
- 2014-07-18 KR KR1020167001943A patent/KR20160033703A/en not_active Application Discontinuation
- 2014-07-18 BR BR112015032235A patent/BR112015032235A2/en not_active IP Right Cessation
- 2014-07-18 JP JP2016528451A patent/JP6474806B2/en active Active
- 2014-07-18 MX MX2016000557A patent/MX2016000557A/en unknown
- 2014-07-18 EP EP14744018.4A patent/EP3024928B1/en active Active
- 2014-07-18 CN CN201480041377.XA patent/CN105392881B/en active Active
-
2016
- 2016-01-22 US US15/004,745 patent/US10724000B2/en active Active
- 2016-09-06 HK HK16110594.1A patent/HK1222414A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003076429A2 (en) * | 2002-03-12 | 2003-09-18 | F. Hoffmann-La Roche Ag | Azepane derivatives and their use as atk1 inhibitors |
WO2010108126A2 (en) * | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
WO2012006577A2 (en) * | 2010-07-08 | 2012-01-12 | Duke University | Direct reprogramming of cells to cardiac myocyte fate |
WO2012022725A2 (en) * | 2010-08-19 | 2012-02-23 | F. Hoffmann-La Roche Ag | Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs) |
Non-Patent Citations (5)
Title |
---|
ARSHAK R. ALEXANIAN ET AL: "Enhancing the efficiency of direct reprogramming of human mesenchymal stem cells into mature neuronal-like cells with the combination of small molecule modulators of chromatin modifying enzymes, SMAD signaling and cyclic adenosine monophosphate levels", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 45, no. 8, 9 May 2013 (2013-05-09), pages 1633 - 1638, XP055111826, ISSN: 1357-2725, DOI: 10.1016/j.biocel.2013.04.022 * |
BREITENLECHNER CHRISTINE B ET AL: "Structure-based optimization of novel azepane derivatives as PKB inhibitors.", JOURNAL OF MEDICINAL CHEMISTRY 11 MAR 2004, vol. 47, no. 6, 11 March 2004 (2004-03-11), pages 1375 - 1390, XP055111930, ISSN: 0022-2623 * |
LADEWIG JULIA ET AL: "Leveling Waddington: the emergence of direct programming and the loss of cell fate hierarchies", NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 14, no. 4, April 2013 (2013-04-01), pages 225 - 236, XP009177358, ISSN: 1471-0072 * |
T. MA ET AL: "Progress in the Reprogramming of Somatic Cells", CIRCULATION RESEARCH, vol. 112, no. 3, 1 February 2013 (2013-02-01), pages 562 - 574, XP055111764, ISSN: 0009-7330, DOI: 10.1161/CIRCRESAHA.111.249235 * |
ZHU JIANGUO ET AL: "Direct conversion of porcine embryonic fibroblasts into adipocytes by chemical molecules.", CELLULAR REPROGRAMMING APR 2012, vol. 14, no. 2, April 2012 (2012-04-01), pages 99 - 105, XP055111928, ISSN: 2152-4998 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11214771B2 (en) | 2014-10-24 | 2022-01-04 | Sumitomo Dainippon Pharma Co., Ltd. | Production method for nerve tissue |
CN116024164A (en) * | 2015-10-21 | 2023-04-28 | 京都府公立大学法人 | Method for producing cells |
JPWO2017069222A1 (en) * | 2015-10-21 | 2018-08-16 | 京都府公立大学法人 | Cell preparation method |
CN109072183A (en) * | 2015-10-21 | 2018-12-21 | 京都府公立大学法人 | The preparation method of cell |
CN109072183B (en) * | 2015-10-21 | 2023-01-20 | 京都府公立大学法人 | Method for producing cell |
JP7228217B2 (en) | 2015-10-21 | 2023-02-24 | 京都府公立大学法人 | Cell preparation method |
WO2017069222A1 (en) * | 2015-10-21 | 2017-04-27 | 京都府公立大学法人 | Cell preparation method |
US11851681B2 (en) * | 2015-10-21 | 2023-12-26 | Kyoto Prefectural Public University Corporation | Cell preparation method |
JP7475723B2 (en) | 2015-10-21 | 2024-04-30 | 京都府公立大学法人 | Cell preparation method |
CN109312306A (en) * | 2016-04-22 | 2019-02-05 | 大日本住友制药株式会社 | The method for generating retinal tissue |
US11371016B2 (en) | 2016-04-22 | 2022-06-28 | Sumitomo Pharma Co., Ltd. | Method for producing retinal tissue |
WO2018090006A1 (en) * | 2016-11-14 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Methods for drug discovery using stem cell-derived schwann cells |
US11959100B2 (en) | 2017-11-30 | 2024-04-16 | Kyoto University | Method for culture of cells |
Also Published As
Publication number | Publication date |
---|---|
US20160369233A1 (en) | 2016-12-22 |
EP3024928B1 (en) | 2018-11-21 |
BR112015032235A2 (en) | 2017-07-25 |
CA2914520A1 (en) | 2015-01-29 |
JP2016528892A (en) | 2016-09-23 |
MX2016000557A (en) | 2016-04-20 |
RU2016105998A3 (en) | 2018-03-30 |
CN105392881B (en) | 2020-09-01 |
KR20160033703A (en) | 2016-03-28 |
EP3024928A1 (en) | 2016-06-01 |
HK1222414A1 (en) | 2017-06-30 |
RU2016105998A (en) | 2017-08-29 |
US10724000B2 (en) | 2020-07-28 |
CN105392881A (en) | 2016-03-09 |
JP6474806B2 (en) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10724000B2 (en) | Small molecule based conversion of somatic cells into neural crest cells | |
AU2014256876B2 (en) | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells | |
WO2015131797A1 (en) | Method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same | |
US20240009248A1 (en) | Methods for generating neural progenitor cells with a spinal cord identity | |
US20150250824A1 (en) | Methods and compositions for expansion of stem cells and other cells | |
JP2016537967A (en) | Production method and application of mammalian retinal stem cells | |
CN110684733A (en) | Midbrain Dopamine (DA) neurons for implantation | |
US20230233617A1 (en) | Methods for differentiating stem cells into dopaminergic progenitor cells | |
KR20190035600A (en) | Differentiation of cortical neurons from human pluripotent stem cells | |
KR101516352B1 (en) | Pharmaceutical composition for the treatment of stroke comprising neural precursor cells derived from human induced pluripotent stem cells | |
WO2011144901A1 (en) | Expansion and directed differentiation of epidermal neural crest stem cells | |
Yang et al. | Efficient conversion of spermatogonial stem cells to phenotypic and functional dopaminergic neurons via the PI3K/Akt and P21/Smurf2/Nolz1 pathway | |
Zhu et al. | Directed differentiation of human embryonic stem cells to neural crest stem cells, functional peripheral neurons, and corneal keratocytes | |
CN107429233B (en) | Method for producing nervous system cell | |
US10231999B2 (en) | Process for preparing cholinergic neurons | |
WO2015143622A1 (en) | Medium for establishing neuroepithelial stem cells and method and use thereof | |
WO2023008564A1 (en) | Method for producing highly proliferative cell, and highly proliferative cell and use thereof | |
WO2017190136A1 (en) | Induction of corneal endothelial cells | |
US12018278B2 (en) | Methods for chemically induced lineage reprogramming | |
Jessberger et al. | Eva C. Thoma,* Claudia Merkl, Tobias Heckel, Rachel Haab, Frederic Knoflach, Corinne Nowaczyk, Nicholas Flint, Ravi Jagasia, Sannah Jensen Zoffmann, Hoa Hue Truong, Pascal Petitjean | |
US20200277567A1 (en) | Methods for chemically induced lineage reprogramming | |
Eridani | Versatile stem cells, young and old. A review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480041377.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14744018 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2914520 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014744018 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015032235 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/000557 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2016528451 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167001943 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2016105998 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015032235 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151222 |